NCT06568172 2026-04-16
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
27 trialsNCT06702033 2026-04-16
MINT-2
Washington University School of Medicine
Phase 2 Recruiting
NCT05691478 2026-04-15
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06325683 2026-04-15
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT01872221 2026-04-14
STEMRI
Institut Claudius Regaud
Phase NA Completed
NCT04708418 2026-04-13
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06097468 2026-04-13
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
University of California, San Francisco
Phase 1/2 Recruiting
NCT07281417 2026-04-13
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT06632327 2026-04-07
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07089641 2026-04-07
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT07515924 2026-04-07
Oral Gallium Maltolate for Recurrent Glioblastoma
Medical College of Wisconsin
Phase EARLY_PHASE1 Not yet recruiting
NCT05710328 2026-04-03
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06114108 2026-04-02
salVage
Swiss Cancer Institute
Phase NA Recruiting
NCT06915727 2026-04-01
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Mayo Clinic
Phase 3 Recruiting
NCT04031677 2026-03-31
STRASS2
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06368817 2026-03-31
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Children's Oncology Group
Phase 2 Recruiting
NCT02366819 2026-03-30
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Suspended
NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT04503694 2026-03-27
REGINA
Jules Bordet Institute
Phase 2 Active not recruiting
NCT05826509 2026-03-27
SUGAR
Institut Claudius Regaud
Phase 2 Active not recruiting
NCT06295809 2026-03-27
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Completed
NCT06850103 2026-03-25
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT04704648 2026-03-23
Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa
AIDS Malignancy Consortium
Phase NA Recruiting
NCT06528691 2026-03-23
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05577416 2026-03-18
AB-218-IIT-201
Melbourne Health
Phase EARLY_PHASE1 Completed
NCT06258525 2026-03-18
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting